Medically reviewed by Shadi Hamdeh, MDMedically reviewed by Shadi Hamdeh, MD Humira (adalimumab) side effects may include ...

possible malignancies and COPD exacerbation Adalimumab (Humira®) Injection site reactions and upper respiratory tract infections Serious bacterial infections, unusual infections (tuberculosis and ...

The anti-inflammatory injection, also known as adalimumab ... Despite retaining its dominance with a 96% market share as of February, Humira's market leadership came under threat in 2024, reaching ...

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event ... aiming to cut injection volume by half and result in fewer injections in particular patients.

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

The anti-inflammatory injection, also known as adalimumab ... After accounting for over a third of its revenue in 2022, Humira's contribution to AbbVie's (ABBV) topline plummeted to ~27% in ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

The injection is given in the thigh or abdomen. The dosage is based on your medical condition and response to treatment. Children's dosage is also based on weight. If you are using this medication ...

possible malignancies and COPD exacerbation Adalimumab (Humira®) Injection site reactions and upper respiratory tract infections Serious bacterial infections, unusual infections (tuberculosis and ...

Yesterday, Amgen announced that it would launch the U.S.’s first marketed Humira-referenced biosimilar, Amjevita (adalimumab-atto), at two different list prices: $3,288 and $1,557 per 40 mg pen ...

AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition. Humira still dominated 96% of ...